Anakuria Therapeutics Inc. has identified rapamycin derivatives acting as mTOR complex 1 (mTORC1) inhibitors reported to be useful for the treatment of diabetic nephropathy, chronic obstructive pulmonary disease, epilepsy, fragile X syndrome, urinary tract infection, heart failure, glaucoma and autosomal dominant polycystic kidney, among others.